Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott T Tagawa

Showing results (151-160 of 208) with videos related to

Pageof 21
Sort By:
Nature Communications|March 19, 2024
The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysisKentaro Ohara, André Figueiredo Rendeiro, Bhavneet Bhinder, et al.
Science Translational Medicine|March 22, 2019
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancerLoredana Puca, Katie Gavyert, Verena Sailer, et al.
Future Oncology (London, England)|November 24, 2025
A plain language summary of the TROPiCS-04 study: sacituzumab govitecan use after platinum-based chemotherapy and immunotherapy in people with locally advanced or metastatic cancer of the bladder, urethra, or upper urinary tractThomas Powles, Scott T Tagawa, Christof Vulsteke, et al.
NPJ Precision Oncology|March 29, 2025
A complex phylogeny of lineage plasticity in metastatic castration resistant prostate cancerJones T Nauseef, Timothy R Chu, William F Hooper, et al.
The New England Journal of Medicine|June 23, 2021
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate CancerOliver Sartor, Johann de Bono, Kim N Chi, et al.
European Urology|February 13, 2018
Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International StudyJoaquin Mateo, Heather H Cheng, Himisha Beltran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2021
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)Jonathan E Rosenberg, Karla A Ballman, Susan Halabi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2024
Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial CancerYohann Loriot, Arjun V Balar, Daniel P Petrylak, et al.
Frontiers in Oncology|January 22, 2025
Initial clinical experience with [<sup>177</sup>Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trialAaron R Hansen, Stephan Probst, Jean-Mathieu Beauregard, et al.
The Prostate|November 20, 2019
PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 studyDaniel P Petrylak, Nicholas J Vogelzang, Kamal Chatta, et al.
Pageof 21

Showing results (151-160 of 208) with videos related to

Sort By:
Pageof 21
Nature Communications|March 19, 2024
The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysisKentaro Ohara, André Figueiredo Rendeiro, Bhavneet Bhinder, et al.
Science Translational Medicine|March 22, 2019
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancerLoredana Puca, Katie Gavyert, Verena Sailer, et al.
Future Oncology (London, England)|November 24, 2025
A plain language summary of the TROPiCS-04 study: sacituzumab govitecan use after platinum-based chemotherapy and immunotherapy in people with locally advanced or metastatic cancer of the bladder, urethra, or upper urinary tractThomas Powles, Scott T Tagawa, Christof Vulsteke, et al.
NPJ Precision Oncology|March 29, 2025
A complex phylogeny of lineage plasticity in metastatic castration resistant prostate cancerJones T Nauseef, Timothy R Chu, William F Hooper, et al.
The New England Journal of Medicine|June 23, 2021
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate CancerOliver Sartor, Johann de Bono, Kim N Chi, et al.
European Urology|February 13, 2018
Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International StudyJoaquin Mateo, Heather H Cheng, Himisha Beltran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2021
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)Jonathan E Rosenberg, Karla A Ballman, Susan Halabi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2024
Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial CancerYohann Loriot, Arjun V Balar, Daniel P Petrylak, et al.
Frontiers in Oncology|January 22, 2025
Initial clinical experience with [<sup>177</sup>Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trialAaron R Hansen, Stephan Probst, Jean-Mathieu Beauregard, et al.
The Prostate|November 20, 2019
PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 studyDaniel P Petrylak, Nicholas J Vogelzang, Kamal Chatta, et al.
Pageof 21